|  |
| --- |
| **PROCEDURE TITLE:** Kidney and Pancreas Pre-transplant Latent Tuberculosis Management |
| **APPLICABLE FACILITIES:**[ ] EHC [ ] EDH [ ] EHH [ ] EHI [ ] EHN [ ] EJCH [ ] ELTAC [x] ESJH[x] EUH [ ] EUHM [ ] EUHS [ ] EUOSH [ ] EWWH [ ] RJV-ERH [ ] RJV-ESOP [x] TEC/ESA |
| **EFFECTIVE DATE:**  | **ORIGINATION DATE:** 08/21/2019 |

**SCOPE:** This policy is necessary for the protection of patients, physicians and staff.

**PURPOSE:** The Emory Transplant Center will comply with all applicable federal, state and local laws, regulations and policies regarding the management patient’s laboratory draws and results.

**PROCEDURE:**

Renal transplant recipients with a history of latent tuberculosis (TB) have risk of development of active TB infection post-transplant. Given these risks the Emory Transplant Center will aim for the following goals:

1. Perform quantiferon gold testing on pre-transplant patients during a Test Now setting or Phase 2.
2. Refer patients to the Infectious Diseases service if a positive quantiferon gold test is received.
3. Will recommend 9 months of isoniazid and pyridoxine therapy that can be managed by transplant ID or a local health department. Therapy will not be required prior to active listing and if not completed prior to transplant appropriate therapy will be initiated by transplant ID upon transplantation.
4. A Tspot will be performed during the admission for transplantation if prior quantiferon gold testing has not previously been obtained or if more than one year has passed since the quantiferon gold testing was completed.

**RELATED DOCUMENTS AND LINKS:** N/A

**DEFINITIONS:** N/A

**REFERENCES AND SOURCES OF EVIDENCE:** N/A

**KEY WORDS:** Tuberculosis, Kidney Transplant, latent TB